New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 19, 2014
13:00 EDTNKTRNektar presents data from Phase l study of etirinotecan pegol
Nektar presented favorable data today from a Phase 1 study of etirinotecan pegol, EP, NKTR-102, in combination with 5-fluorouracil, 5-FU/Leucovorin LV, in patients with advanced cancer. NKTR-102 is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. These new data were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
13:08 EDTNKTRNektar volatility increases on start of Phase 3 study of NKTR-181
Nektar March call option implied volatility is at 87, April is at 78, May is at 74; compared to its 26-week average of 70 according to Track Data, suggesting large near term price movement on the announcement of the start of Phase 3 study of NKTR-181.
09:28 EDTNKTRNektar announces start of Phase 3 study of NKTR-181
Nektar announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of entry into the brain. The company said this slow rate of entry is designed to reduce the euphoria that can lead to the abuse of current opioid analgesics. SUMMIT-07 will evaluate the efficacy, safety and tolerability of NKTR-181 in patients with chronic low back pain who are also opioid-na´ve. NKTR-181 is a new chemical entity that was created using Nektar's proprietary small molecule polymer conjugate technology. NKTR-181 has several potential differentiating properties that are inherent to the structure of the molecule, including a slow rate of entry into the CNS as measured by pupillometry and a plasma pharmacokinetic profile that supports twice-daily oral dosing. NKTR-181 is not a reformulation of a marketed opioid, which is a commonly-used method to attempt to prevent the manipulation of existing long-acting opioid drugs into more abusable forms. NKTR-181 has been granted has been granted Fast Track designation for the treatment of moderate to severe chronic pain by the U.S. Food and Drug Administration.
February 24, 2015
17:00 EDTNKTRNektar reports Q4 EPS (35c), consensus (36c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use